Jones D - Search Results

1

Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology.

Jones D, Kamel-Reid S, Bahler D, Dong H, Elenitoba-Johnson K, Press R, Quigley N, Rothberg P, Sabath D, Viswanatha D, Weck K, Zehnder J. Jones D, et al. J Mol Diagn. 2009 Jan;11(1):4-11. doi: 10.2353/jmoldx.2009.080095. Epub 2008 Dec 18. J Mol Diagn. 2009. PMID: 19095773 Free PMC article.

2

Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.

Kantarjian HM, Cortes JE, O'Brien S, Luthra R, Giles F, Verstovsek S, Faderl S, Thomas D, Garcia-Manero G, Rios MB, Shan J, Jones D, Talpaz M. Kantarjian HM, et al. Among authors: jones d. Blood. 2004 Oct 1;104(7):1979-88. doi: 10.1182/blood-2004-02-0711. Epub 2004 Jun 15. Blood. 2004. PMID: 15198956 Free article.

3

Quantitative PCR detection of t(14;18) bcl-2/JH fusion sequences in follicular lymphoma patients: comparison of peripheral blood and bone marrow aspirate samples.

Bowman A, Jones D, Medeiros LJ, Luthra R. Bowman A, et al. Among authors: jones d. J Mol Diagn. 2004 Nov;6(4):396-400. doi: 10.1016/S1525-1578(10)60537-5. J Mol Diagn. 2004. PMID: 15507680 Free PMC article.

4

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.

Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H. Cortes J, et al. Among authors: jones d. Clin Cancer Res. 2005 May 1;11(9):3425-32. doi: 10.1158/1078-0432.CCR-04-2139. Clin Cancer Res. 2005. PMID: 15867244 Clinical Trial.

5

inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases.

Merzianu M, Medeiros LJ, Cortes J, Yin C, Lin P, Jones D, Glassman A, Kantarjian H, Huh Y. Merzianu M, et al. Among authors: jones d. Am J Clin Pathol. 2005 Nov;124(5):807-14. doi: 10.1309/3HFE-16DK-MB1D-BFMN. Am J Clin Pathol. 2005. PMID: 16203287

6

Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.

Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R, Giles F, Andersson BS, Champlin R, de Lima M. Jabbour E, et al. Among authors: jones r, jones d. Blood. 2006 Aug 15;108(4):1421-3. doi: 10.1182/blood-2006-02-001933. Epub 2006 Apr 6. Blood. 2006. PMID: 16601247 Free article.

7

Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.

Kantarjian HM, Talpaz M, O'Brien S, Jones D, Giles F, Garcia-Manero G, Faderl S, Ravandi F, Rios MB, Shan J, Cortes J. Kantarjian HM, et al. Among authors: jones d. Blood. 2006 Sep 15;108(6):1835-40. doi: 10.1182/blood-2006-02-004325. Epub 2006 May 18. Blood. 2006. PMID: 16709931 Free article. Clinical Trial.

8

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.

Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, Cortes J. Jabbour E, et al. Among authors: jones d. Leukemia. 2006 Oct;20(10):1767-73. doi: 10.1038/sj.leu.2404318. Epub 2006 Jul 20. Leukemia. 2006. PMID: 16855631

9

Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.

Quintas-Cardama A, Kantarjian H, Jones D, Nicaise C, O'Brien S, Giles F, Talpaz M, Cortes J. Quintas-Cardama A, et al. Among authors: jones d. Blood. 2007 Jan 15;109(2):497-9. doi: 10.1182/blood-2006-07-035493. Epub 2006 Sep 21. Blood. 2007. PMID: 16990591 Free article. Clinical Trial.

10

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.

Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ. Giles FJ, et al. Among authors: jones d. Blood. 2007 Jan 15;109(2):500-2. doi: 10.1182/blood-2006-05-025049. Epub 2006 Sep 21. Blood. 2007. PMID: 16990603 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

15,060 results

Search Page